David M Lang

Publications (14)88.94 Total impact

• Source

  Available from: Marcus Maurer

  Article: International consensus on hereditary and acquired angioedema.

  David M Lang, Werner Aberer, Jonathan A Bernstein, Hiok Hee Chng, Anete Sevciovic Grumach, Michihiro Hide, Marcus Maurer, Richard Weber, Bruce Zuraw
  Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 12/2012; 109(6):395-402. · 2.83 Impact Factor
• Article: Adverse reactions to vaccines practice parameter 2012 update.

  John M Kelso, Matthew J Greenhawt, James T Li, Richard A Nicklas, David I Bernstein, Joann Blessing-Moore, Linda Cox, David Khan, David M Lang, John Oppenheimer, Jay M Portnoy, Christopher R Randolph, Diane E Schuller, Sheldon L Spector, Stephen A Tilles, Dana Wallace
  The Journal of allergy and clinical immunology 05/2012; 130(1):25-43. · 9.17 Impact Factor
• Article: Environmental assessment and exposure control: a practice parameter--furry animals.

  Jay Portnoy, Kevin Kennedy, James Sublett, Wanda Phipatanakal, Elizabeth Matsui, Charles Barnes, Carl Grimes, J David Miller, James M Seltzer, P Brock Williams, Jonathan A Bernstein, David I Bernstein, Joann Blessing-Moore, Linda Cox, David A Khan, David M Lang, Richard A Nicklas, John Oppenheimer
  Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 04/2012; 108(4):223.e1-15. · 2.83 Impact Factor
• Article: Stinging insect hypersensitivity: a practice parameter update 2011.

  David B K Golden, John Moffitt, Richard A Nicklas, Theodore Freeman, David F Graft, Robert E Reisman, James M Tracy, David Bernstein, Joann Blessing-Moore, Linda Cox, David A Khan, David M Lang, John Oppenheimer, Jay M Portnoy, Christopher Randolph, Diane E Schuller, Sheldon L Spector, Steven A Tilles, Dana Wallace
  [show abstract] [hide abstract]
  ABSTRACT: These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing "Stinging insect hypersensitivity: a practice parameter update II." Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or the ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, and the Joint Council of Allergy, Asthma and Immunology. This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. These parameters are not designed for use by pharmaceutical companies in drug promotion. The Joint Task Force understands that the cost of diagnostic tests and therapeutic agents is an important concern that may appropriately influence the work-up and treatment chosen for a given patient. The Joint Task Force recognizes that the emphasis of our primary recommendations regarding a medication may vary, for example, depending on third party payer issues and product patent expiration dates. However, since a given test or agent's cost is so widely variable, and there is a paucity of pharmacoeconomic data, the Joint Task Force generally does not consider cost when formulating Practice Parameter recommendations. In extraordinary circumstances, when the cost benefit of an intervention is prohibitive as supported by pharmacoeconomic data, commentary may be provided.
  The Journal of allergy and clinical immunology 04/2011; 127(4):852-4.e1-23. · 9.17 Impact Factor
• Source

  Available from: Stephen A Tilles

  Article: Administering influenza vaccine to egg allergic recipients: a focused practice parameter update.

  Matthew J Greenhawt, James T Li, David I Bernstein, Joann Blessing-Moore, Linda Cox, David Khan, David M Lang, Richard A Nicklas, John Oppenheimer, Jay M Portnoy, Christopher Randolph, Diane E Schuller, Sheldon L Spector, Stephen A Tilles, Dana Wallace
  Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 01/2011; 106(1):11-6. · 2.83 Impact Factor
• Source

  Available from: Stephen A Tilles

  Article: Allergen immunotherapy: a practice parameter third update.

  Linda Cox, Harold Nelson, Richard Lockey, Christopher Calabria, Thomas Chacko, Ira Finegold, Michael Nelson, Richard Weber, David I Bernstein, Joann Blessing-Moore, David A Khan, David M Lang, Richard A Nicklas, John Oppenheimer, Jay M Portnoy, Christopher Randolph, Diane E Schuller, Sheldon L Spector, Stephen Tilles, Dana Wallace
  The Journal of allergy and clinical immunology 01/2011; 127(1 Suppl):S1-55. · 9.17 Impact Factor
• Source

  Available from: Sergio Bonini

  Article: Pathogenesis, prevalence, diagnosis, and management of exercise-induced bronchoconstriction: a practice parameter.

  John M Weiler, Sandra D Anderson, Christopher Randolph, Sergio Bonini, Timothy J Craig, David S Pearlman, Kenneth W Rundell, William S Silvers, William W Storms, David I Bernstein, [......], Diane E Schuller, Sheldon L Spector, Stephen A Tilles, Dana Wallace, William Henderson, Lawrence Schwartz, David Kaufman, Talal Nsouli, Lawrence Shieken, Nelson Rosario
  Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 12/2010; 105(6 Suppl):S1-47. · 2.83 Impact Factor
• Source

  Available from: Stephen A Tilles

  Article: The diagnosis and management of anaphylaxis practice parameter: 2010 update.

  Phillip Lieberman, Richard A Nicklas, John Oppenheimer, Stephen F Kemp, David M Lang, David I Bernstein, Jonathan A Bernstein, A Wesley Burks, Anna M Feldweg, Jordan N Fink, [......], Joann Blessing-Moore, Linda Cox, David A Khan, David Lang, Jay M Portnoy, Christopher Randolph, Diane E Schuller, Sheldon L Spector, Stephen Tilles, Dana Wallace
  [show abstract] [hide abstract]
  ABSTRACT: These parameters were developed by the Joint Task Force on Practice Parameters, representing the American Academy of Allergy, Asthma & Immunology (AAAAI); the American College of Allergy, Asthma & Immunology (ACAAI); and the Joint Council of Allergy, Asthma and Immunology. The AAAAI and the ACAAI have jointly accepted responsibility for establishing "The Diagnosis and Management of Anaphylaxis Practice Parameter: 2010 Update." This is a complete and comprehensive document at the current time. The medical environment is a changing environment, and not all recommendations will be appropriate for all patients. Because this document incorporated the efforts of many participants, no single individual, including those who served on the Joint Task Force, is authorized to provide an official AAAAI or ACAAI interpretation of these practice parameters. Any request for information about or an interpretation of these practice parameters by the AAAAI or ACAAI should be directed to the Executive Offices of the AAAAI, the ACAAI, or the Joint Council of Allergy, Asthma and Immunology. These parameters are not designed for use by pharmaceutical companies in drug promotion.
  The Journal of allergy and clinical immunology 09/2010; 126(3):477-80.e1-42. · 9.17 Impact Factor
• Article: Effectiveness of Helicobacter pylori eradication in chronic urticaria: evidence-based analysis using the Grading of Recommendations Assessment, Development, and Evaluation system.

  Ali Shakouri, Enrico Compalati, David M Lang, David A Khan
  [show abstract] [hide abstract]
  ABSTRACT: Chronic urticaria is a common and often frustrating condition that physicians encounter in the outpatient setting. Its management continues to be a challenge, and an exogenous cause for chronic urticaria is only found rarely. Helicobacter pylori has been implicated as a factor for many disorders and proposed as an etiologic factor for chronic urticaria. We aim to provide a comprehensive review of the data on H. pylori eradication for treatment of chronic urticaria by utilizing the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) approach to analyze and determine the quality of evidence for this proposed therapy. Although H. pylori eradication has been recommended as part of routine chronic urticaria management by multiple authors, the trials of H. pylori eradication in the treatment of chronic urticaria have yielded conflicting results and suffer from substantial methodological limitations. Our critical appraisal of the 10 trials showing the benefit of H. pylori eradication in patients with chronic urticaria leads to an overall very low grade for this intervention. Appraisal of nine studies in which H. pylori eradication showed no benefit in the course of chronic urticaria also leads to an overall very low grade. The evidence that H. pylori eradication leads to improvement of chronic urticaria outcomes is weak and conflicting; this leads to a weak recommendation for routine H. pylori eradication for patients with chronic urticaria. For this reason, a decision to proceed with this management should be considered carefully in the context of relative harms/burdens and benefits, as well as patient values and preferences.
  Current Opinion in Allergy and Clinical Immunology 08/2010; 10(4):362-9. · 4.11 Impact Factor
• Source

  Available from: Joseph Bellanti

  Article: Adverse reactions to vaccines.

  John M Kelso, James T Li, Richard A Nicklas, Joann Blessing-Moore, Linda Cox, David M Lang, John Oppenheimer, Jay M Portnoy, Christopher Randolph, Diane E Schuller, Sheldon L Spector, Stephen Tilles, Dana Wallace, Zuhair K Ballas, James R Baker, Joseph A Bellanti, Daniel Ein, Leslie C Grammer
  Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 10/2009; 103(4 Suppl 2):S1-14. · 2.83 Impact Factor
• Source

  Available from: Stephen A Tilles

  Article: The diagnosis and management of rhinitis: an updated practice parameter.

  Dana V Wallace, Mark S Dykewicz, David I Bernstein, Joann Blessing-Moore, Linda Cox, David A Khan, David M Lang, Richard A Nicklas, John Oppenheimer, Jay M Portnoy, Christopher C Randolph, Diane Schuller, Sheldon L Spector, Stephen A Tilles
  The Journal of allergy and clinical immunology 09/2008; 122(2 Suppl):S1-84. · 9.17 Impact Factor
• Source

  Available from: Estelle Levetin

  Article: Allergy diagnostic testing: an updated practice parameter.

  I Leonard Bernstein, James T Li, David I Bernstein, Robert Hamilton, Sheldon L Spector, Ricardo Tan, Scott Sicherer, David B K Golden, David A Khan, Richard A Nicklas, [......], Joann Blessing-Moore, Linda Cox, David M Lang, John Oppenheimer, Christopher C Randolph, Diane E Schuller, Stephen A Tilles, Dana V Wallace, Estelle Levetin, Richard Weber
  Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 04/2008; 100(3 Suppl 3):S1-148. · 2.83 Impact Factor
• Article: The diagnosis and management of sinusitis: a practice parameter update.

  Raymond G Slavin, Sheldon L Spector, I Leonard Bernstein, Michael A Kaliner, David W Kennedy, Frank S Virant, Ellen R Wald, David A Khan, Joann Blessing-Moore, David M Lang, Richard A Nicklas, John J Oppenheimer, Jay M Portnoy, Diane E Schuller, Stephen A Tilles, Larry Borish, Robert A Nathan, Brian A Smart, Mark L Vandewalker
  Journal of Allergy and Clinical Immunology 01/2006; 116(6 Suppl):S13-47. · 11.00 Impact Factor
• Source

  Available from: aaaai.org

  Article: Stinging insect hypersensitivity: a practice parameter update.

  John E Moffitt, David B K Golden, Robert E Reisman, Rufus Lee, Richard Nicklas, Theodore Freeman, Richard deshazo, James Tracy, I Leonard Bernstein, Joann Blessing-Moore, David A Khan, David M Lang, Jay M Portnoy, Diane E Schuller, Sheldon L Spector, Steven A Tilles
  Journal of Allergy and Clinical Immunology 11/2004; 114(4):869-86. · 11.00 Impact Factor